Josep Julve

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5521292/publications.pdf

Version: 2024-02-01

109	2,286	230014	299063
papers	citations	27 h-index	42 g-index

120	120	120	3448
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Advanced lipoprotein profile in individuals with normal and impaired glucose metabolism. Revista Espanola De Cardiologia (English Ed), 2022, 75, 22-30.	0.4	5
2	Perfil lipoproteico avanzado en individuos con metabolismo glucÃ©mico normal y alterado. Revista Espanola De Cardiologia, 2022, 75, 22-30.	0.6	5
3	MiR-125b downregulates macrophage scavenger receptor type B1 and reverse cholesterol transport. Biomedicine and Pharmacotherapy, 2022, 146, 112596.	2.5	4
4	Assessment of Ex Vivo Potential of Murine HDL in. Methods in Molecular Biology, 2022, 2419, 283-292.	0.4	0
5	Monitoring Atheroprotective Macrophage Cholesterol. Methods in Molecular Biology, 2022, 2419, 569-581.	0.4	1
6	TMAO and Gut Microbial-Derived Metabolites TML and Î³BB Are Not Associated with Thrombotic Risk in Patients with Venous Thromboembolism. Journal of Clinical Medicine, 2022, 11, 1425.	1.0	2
7	High-Density Lipoproteins and Cardiovascular Disease: The Good, the Bad, and the Future II. Biomedicines, 2022, 10, 620.	1.4	1
8	Beneficial effects of olive oil and Mediterranean diet on cancer physio-pathology and incidence. Seminars in Cancer Biology, 2021, 73, 178-195.	4.3	24
9	Atherogenic dyslipidemia, but not hyperglycemia, is an independent factor associated with liver fibrosis in subjects with type 2 diabetes and NAFLD: a population-based study. European Journal of Endocrinology, 2021, 184, 587-596.	1.9	12
10	Reverse Cholesterol Transport Dysfunction Is a Feature of Familial Hypercholesterolemia. Current Atherosclerosis Reports, 2021, 23, 29.	2.0	8
11	Nicotinamide Protects Against Dietâ€Induced Body Weight Gain, Increases Energy Expenditure, and Induces White Adipose Tissue Beiging. Molecular Nutrition and Food Research, 2021, 65, e2100111.	1.5	9
12	High-Density Lipoproteins and Cardiovascular Disease: The Good, the Bad, and the Future. International Journal of Molecular Sciences, 2021, 22, 7488.	1.8	4
13	Impact of Dietary Lipids on the Reverse Cholesterol Transport: What We Learned from Animal Studies. Nutrients, 2021, 13, 2643.	1.7	14
14	High-Density Lipoproteins and Cardiovascular Disease: The Good, the Bad and the Future. Biomedicines, 2021, 9, 857.	1.4	2
15	Apolipoprotein and LRP1-Based Peptides as New Therapeutic Tools in Atherosclerosis. Journal of Clinical Medicine, 2021, 10, 3571.	1.0	6
16	The Capacity of APOB-Depleted Plasma in Inducing ATP-Binding Cassette A1/G1-Mediated Macrophage Cholesterol Effluxâ€"But Not Gut Microbial-Derived Metabolitesâ€"Is Independently Associated with Mortality in Patients with ST-Segment Elevation Myocardial Infarction. Biomedicines, 2021, 9, 1336.	1.4	3
17	Psychometric Validation of the Cardiff Wound Impact Schedule Questionnaire in a Spanish Population with Diabetic Foot Ulcer. Journal of Clinical Medicine, 2021, 10, 4023.	1.0	2
18	Previous Vitamin D Supplementation and Morbidity and Mortality Outcomes in People Hospitalised for COVID19: A Cross-Sectional Study. Frontiers in Public Health, 2021, 9, 758347.	1.3	8

#	Article	IF	Citations
19	1H-magnetic resonance spectroscopy lipoprotein profile in patients with chronic heart failure versus matched controls. Revista Espanola De Cardiologia (English Ed), 2021, , .	0.4	1
20	Outstanding improvement of the advanced lipoprotein profile in subjects with new-onset type 1 diabetes mellitus after achieving optimal glycemic control. Diabetes Research and Clinical Practice, 2021, 182, 109145.	1.1	6
21	Associations Between Diabetic Retinopathy and Parkinson's Disease: Results From the Catalonian Primary Care Cohort Study. Frontiers in Medicine, 2021, 8, 800973.	1.2	6
22	NAD+-Increasing Strategies to Improve Cardiometabolic Health?. Frontiers in Endocrinology, 2021, 12, 815565.	1.5	4
23	Therapeutic Potential of Emerging NAD+-Increasing Strategies for Cardiovascular Diseases. Antioxidants, 2021, 10, 1939.	2.2	11
24	Advanced Quantitative Lipoprotein Characteristics Do Not Relate to Healthy Dietary Patterns in Adults from a Mediterranean Area. Nutrients, 2021, 13, 4369.	1.7	1
25	Nicotinamide Prevents Apolipoprotein B-Containing Lipoprotein Oxidation, Inflammation and Atherosclerosis in Apolipoprotein E-Deficient Mice. Antioxidants, 2020, 9, 1162.	2.2	11
26	LDL Receptor Regulates the Reverse Transport of Macrophage-Derived Unesterified Cholesterol via Concerted Action of the HDL-LDL Axis. Circulation Research, 2020, 127, 778-792.	2.0	45
27	Subcutaneous Administration of Apolipoprotein J-Derived Mimetic Peptide d-[113â€“122]apoJ Improves LDL and HDL Function and Prevents Atherosclerosis in LDLR-KO Mice. Biomolecules, 2020, 10, 829.	1.8	18
28	Human ApoA-I Overexpression Enhances Macrophage-Specific Reverse Cholesterol Transport but Fails to Prevent Inherited Diabesity in Mice. International Journal of Molecular Sciences, 2019, 20, 655.	1.8	6
29	Molecular analysis of APOB, SAR1B, ANGPTL3, and MTTP in patients with primary hypocholesterolemia in a clinical laboratory setting: Evidence supporting polygenicity in mutation-negative patients. Atherosclerosis, 2019, 283, 52-60.	0.4	15
30	Phytosterols in Cancer: From Molecular Mechanisms to Preventive and Therapeutic Potentials. Current Medicinal Chemistry, 2019, 26, 6735-6749.	1.2	37
31	Vitamin B3 impairs reverse cholesterol transport in Apolipoprotein E-deficient mice. ClÃnica E InvestigaciÃ³n En Arteriosclerosis (English Edition), 2019, 31, 251-260.	0.1	0
32	Novel Insights into the Role of HDL-Associated Sphingosine-1-Phosphate in Cardiometabolic Diseases. International Journal of Molecular Sciences, 2019, 20, 6273.	1.8	18
33	Vitamin B3 impairs reverse cholesterol transport in Apolipoprotein E-deficient mice. ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2019, 31, 251-260.	0.4	2
34	Altered HDL Remodeling and Functionality in Familial Hypercholesterolemia. Journal of the American College of Cardiology, 2018, 71, 466-468.	1.2	13
35	Autosomal dominant hypercholesterolemia in Catalonia: Correspondence between clinical-biochemical and genetic diagnostics in 967 patients studied in a multicenter clinical setting. Journal of Clinical Lipidology, 2018, 12, 1452-1462.	0.6	14
36	Administration of CORM-2 inhibits diabetic neuropathy but does not reduce dyslipidemia in diabetic mice. PLoS ONE, 2018, 13, e0204841.	1.1	12

#	Article	IF	Citations
37	A rare STAP1 mutation incompletely associated with familial hypercholesterolemia. Clinica Chimica Acta, 2018, 487, 270-274.	0.5	19
38	LXR-dependent regulation of macrophage-specific reverse cholesterol transport is impaired in a model of genetic diabesity. Translational Research, 2017, 186, 19-35.e5.	2.2	5
39	Hepatic CD36 downregulation parallels steatosis improvement in morbidly obese undergoing bariatric surgery. International Journal of Obesity, 2017, 41, 1388-1393.	1.6	11
40	A novel homozygous mutation causing lecithinâ€“cholesterol acyltransferase deficiency in a proband of Romanian origin with a record of extreme gestational hyperlipidemia. Journal of Clinical Lipidology, 2017, 11, 1475-1479.e3.	0.6	6
41	Human hepatic lipase overexpression in mice induces hepatic steatosis and obesity through promoting hepatic lipogenesis and white adipose tissue lipolysis and fatty acid uptake. PLoS ONE, 2017, 12, e0189834.	1.1	21
42	Consumption of polyunsaturated fat improves the saturated fatty acid-mediated impairment of HDL antioxidant potential. Atherosclerosis, 2016, 252, e210.	0.4	0
43	Chylomicrons: Advances in biology, pathology, laboratory testing, and therapeutics. Clinica Chimica Acta, 2016, 455, 134-148.	0.5	59
44	Chronic intermittent psychological stress promotes macrophage reverse cholesterol transport by impairing bile acid absorption in mice. Physiological Reports, 2015, 3, e12402.	0.7	21
45	Consumption of polyunsaturated fat improves the saturated fatty acidâ€mediated impairment of HDL antioxidant potential. Molecular Nutrition and Food Research, 2015, 59, 1987-1996.	1.5	16
46	PPAR-Î²/Î´ activation promotes phospholipid transfer protein expression. Biochemical Pharmacology, 2015, 94, 101-108.	2.0	23
47	Enhanced vascular permeability facilitates entry of plasma HDL and promotes macrophage-reverse cholesterol transport from skin in mice. Journal of Lipid Research, 2015, 56, 241-253.	2.0	14
48	Hypoxia worsens the impact of intracellular triglyceride accumulation promoted by electronegative low-density lipoprotein in cardiomyocytes by impairing perilipin 5 upregulation. International Journal of Biochemistry and Cell Biology, 2015, 65, 257-267.	1.2	12
49	HDL and Lifestyle Interventions. Handbook of Experimental Pharmacology, 2015, 224, 569-592.	0.9	19
50	Quantification of In Vitro Macrophage Cholesterol Efflux and In Vivo Macrophage-Specific Reverse Cholesterol Transport. Methods in Molecular Biology, 2015, 1339, 211-233.	0.4	29
51	Remarkable quantitative and qualitative differences in HDL after niacin or fenofibrate therapy in type 2 diabetic patients. Atherosclerosis, 2015, 238, 213-219.	0.4	23
52	Sitosterolemia: Diagnosis, Investigation, and Management. Current Atherosclerosis Reports, 2014, 16, 424.	2.0	92
53	Molecular analysis of chylomicronemia in a clinical laboratory setting: Diagnosis of 13 cases of lipoprotein lipase deficiency. Clinica Chimica Acta, 2014, 429, 61-68.	0.5	34
54	Bariatric surgery in morbidly obese patients improves the atherogenic qualitative properties of the plasma lipoproteins. Atherosclerosis, 2014, 234, 200-205.	0.4	29

#	Article	IF	Citations
55	Macrophage-to-feces reverse cholesterol transport is impaired in a mouse model of diabetes. Atherosclerosis, 2014, 235, e182-e183.	0.4	0
56	Both hepatic lipase- and endothelial lipase-deficiency improve two major antiatherogenic properties of HDL in knockout mice. Atherosclerosis, 2014, 235, e32.	0.4	0
57	Effect of bariatric surgery in morbidly obese patients on the quantitative and qualitative characteristics of plasma lipoproteins. Atherosclerosis, 2014, 235, e249.	0.4	0
58	Resveratrol administration or SIRT1 overexpression does not increase LXR signaling and macrophage-to-feces reverse cholesterol transport inÂvivo. Translational Research, 2013, 161, 110-117.	2.2	8
59	Hepatic lipase- and endothelial lipase-deficiency in mice promotes macrophage-to-feces RCT and HDL antioxidant properties. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2013, 1831, 691-697.	1.2	24
60	Phytosterols inhibit the tumor growth and lipoprotein oxidizability induced by a high-fat diet in mice with inherited breast cancer. Journal of Nutritional Biochemistry, 2013, 24, 39-48.	1.9	41
61	Structural and functional analysis of APOA5 mutations identified in patients with severe hypertriglyceridemia. Journal of Lipid Research, 2013, 54, 649-661.	2.0	34
62	Methionineâ€induced hyperhomocysteinemia impairs the antioxidant ability of highâ€density lipoproteins without reducing in vivo macrophageâ€specific reverse cholesterol transport. Molecular Nutrition and Food Research, 2013, 57, 1814-1824.	1.5	18
63	Reciprocal Negative Cross-Talk between Liver X Receptors (LXRs) and STAT1: Effects on IFN-Î³â€“Induced Inflammatory Responses and LXR-Dependent Gene Expression. Journal of Immunology, 2013, 190, 6520-6532.	0.4	44
64	Human scavenger protein AIM increases foam cell formation and CD36-mediated oxLDL uptake. Journal of Leukocyte Biology, 2013, 95, 509-520.	1.5	36
65	Acute Psychological Stress Accelerates Reverse Cholesterol Transport via Corticosterone-Dependent Inhibition of Intestinal Cholesterol Absorption. Circulation Research, 2012, 111, 1459-1469.	2.0	28
66	Identification of a novel mutation in the ANGPTL3 gene in two families diagnosed of familial hypobetalipoproteinemia without APOB mutation. Clinica Chimica Acta, 2012, 413, 552-555.	0.5	63
67	Differential effects of gemfibrozil and fenofibrate on reverse cholesterol transport from macrophages to feces in vivo. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2011, 1811, 104-110.	1.2	25
68	ATP-binding cassette G5/G8 deficiency causes hypertriglyceridemia by affecting multiple metabolic pathways. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2011, 1811, 1186-1193.	1.2	20
69	The Cholesterol Content of Western Diets Plays a Major Role in the Paradoxical Increase in High-Density Lipoprotein Cholesterol and Upregulates the Macrophage Reverse Cholesterol Transport Pathway. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 2493-2499.	1.1	64
70	Seeking Novel Targets for Improving In Vivo Macrophage-Specific Reverse Cholesterol Transport: Translating Basic Science into New Therapies for the Prevention and Treatment of Atherosclerosis. Current Vascular Pharmacology, 2011, 9, 220-237.	0.8	13
71	Fatty liver and fibrosis in glycine N-methyltransferase knockout mice is prevented by nicotinamide. Hepatology, 2010, 52, 105-114.	3.6	81
72	Proteomic analysis of electronegative low-density lipoprotein. Journal of Lipid Research, 2010, 51, 3508-3515.	2.0	56

#	Article	IF	Citations
73	Human Apolipoprotein A-II Determines Plasma Triglycerides by Regulating Lipoprotein Lipase Activity and High-Density Lipoprotein Proteome. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 232-238.	1.1	69
74	La apolipoproteÃna A-II altera la composiciÃ³n apolipoproteica de HDL y su capacidad para activar la lipoproteÃna lipasa. ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2010, 22, 192-197.	0.4	1
75	Â¿Son todas las partÃculas de lipoproteÃnas de alta densidad iguales?. ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2010, 22, 22-25.	0.4	0
76	In vivo macrophage-specific RCT and antioxidant and antiinflammatory HDL activity measurements: New tools for predicting HDL atheroprotection. Atherosclerosis, 2009, 206, 321-327.	0.4	56
77	Efecto de la expresiÃ³n de la PTEC, el gemfibrozilo y la rosiglitazona en el transporte inverso de colesterol desde macrÃ³fagos a heces in vivo. ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2009, 21, 232-239.	0.4	0
78	Unraveling the functions of macrophage transporters by measuring macrophage-specific reverse cholesterol transport inÂvivo. Future Lipidology, 2007, 2, 609-613.	0.5	0
79	Differential intestinal mucosal protein expression in hypercholesterolemic mice fed a phytosterolâ€enriched diet. Proteomics, 2007, 7, 2659-2666.	1.3	9
80	Deficiency in monocyte chemoattractant protein-1 modifies lipid and glucose metabolism. Experimental and Molecular Pathology, 2007, 83, 361-366.	0.9	26
81	Human adipose tissue as a source of Flk-1 cells: new method of differentiation and expansion. Cardiovascular Research, 2005, 65, 328-333.	1.8	80
82	Paradoxical exacerbation of combined hyperlipidemia in human apolipoprotein A-II transgenic mice treated with fenofibrate. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2005, 1737, 130-137.	1.2	20
83	Human Apolipoprotein A-II Enrichment Displaces Paraoxonase From HDL and Impairs Its Antioxidant Properties. Circulation Research, 2004, 95, 789-797.	2.0	118
84	DetecciÃ³n y caracterizaciÃ³n de la lipoproteÃna X en una paciente con colestasis. ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2003, 15, 106-110.	0.4	0
85	Postprandial lipidemia is normal in non-obese type 2 diabetic patients with relatively preserved insulin secretion. Metabolism: Clinical and Experimental, 2003, 52, 1038-1042.	1.5	7
86	Inactive hepatic lipase in rat plasma. Journal of Lipid Research, 2003, 44, 2250-2256.	2.0	7
87	On the Mechanisms by Which Human Apolipoprotein A-II Gene Variability Relates to Hypertriglyceridemia. Circulation, 2002, 105, e129; author reply e129.	1.6	3
88	Mechanisms of HDL deficiency in mice overexpressing human apoA-II. Journal of Lipid Research, 2002, 43, 1734-1742.	2.0	25
89	Ãšltimos conocimientos sobre los PPARÎ±. ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2002, 14, 217-218.	0.4	0
90	Ultracentrifugation Micromethod for Preparation of Small Experimental Animal Lipoproteins. Analytical Biochemistry, 2002, 303, 73-77.	1.1	16

#	Article	IF	Citations
91	Overexpression of human apolipoprotein A-II in transgenic mice does not increase their susceptibility to insulin resistance and obesity. Diabetologia, 2002, 45, 600-601.	2.9	14
92	ApoA-IMALLORCA impairs LCAT activation and induces dominant familial hypoalphalipoproteinemia. Journal of Lipid Research, 2002, 43, 115-123.	2.0	24
93	ApoA-I(MALLORCA) impairs LCAT activation and induces dominant familial hypoalphalipoproteinemia. Journal of Lipid Research, 2002, 43, 115-23.	2.0	18
94	Anomalous lipoproteins in obese Zucker rats. Diabetes, Obesity and Metabolism, 2001, 3, 259-270.	2.2	13
95	Lipoprotein Lipase and Cholesterol Transfer Activities of Lean and Obese Zucker Rats. Hormone and Metabolic Research, 2001, 33, 458-462.	0.7	6
96	Role of apoA-II in lipid metabolism and atherosclerosis: advances in the study of an enigmatic protein. Journal of Lipid Research, 2001, 42, 1727-1739.	2.0	118
97	ApoA-II expression in CETP transgenic mice increases VLDL production and impairs VLDL clearance. Journal of Lipid Research, 2001, 42, 241-248.	2.0	42
98	Effect of Fasting on Hepatic Lipase Activity in the Liver of Developing Rats. Neonatology, 2000, 77, 131-138.	0.9	2
99	Increased production of very-low-density lipoproteins in transgenic mice overexpressing human apolipoprotein A-II and fed with a high-fat diet. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2000, 1488, 233-244.	1.2	31
100	Expression of human apolipoprotein (apo) A-II in apoE deficient mice reproduces the effects of a major familial combined hyperlipidemia gene. Atherosclerosis, 2000, 151, 66.	0.4	0
101	Increased production of very low density lipoproteins in transgenic mice overexpressing human apolipoprotein A-II: A mouse model of familial combined hyperlipidemia. Atherosclerosis, 2000, 151, 77.	0.4	1
102	Expression of human apolipoprotein A-II in apolipoprotein E-deficient mice induces features of familial combined hyperlipidemia. Journal of Lipid Research, 2000, 41, 1328-1338.	2.0	59
103	Distribution of Oleoyl-Estrone in Rat Plasma Lipoproteins. Hormone and Metabolic Research, 1999, 31, 597-601.	0.7	28
104	Free cholesterol deposition in the cornea of human apolipoprotein A-II transgenic mice with functional lecithin: Cholesterol acyltransferase deficiency. Metabolism: Clinical and Experimental, 1999, 48, 415-421.	1.5	23
105	Molecular Diagnosis of Lecithin: Cholesterol Acyltransferase Deficiency in a Presymptomatic Proband. Clinical Chemistry and Laboratory Medicine, 1998, 36, 443-8.	1.4	5
106	Hormonal regulation of lipoprotein lipase activity from 5-day-old rat hepatocytes. Molecular and Cellular Endocrinology, 1996, 116, 97-104.	1.6	32
107	Decrease in the expression of hepatic lipase activity following partial hepatectomy. Lipids and Lipid Metabolism, 1996, 1302, 193-198.	2.6	6
108	Hepatic regeneration induces changes in lipoprotein lipase activity in several tissues and its re-expression in the liver. Biochemical Journal, 1996, 318, 597-602.	1.7	26

#	Article	IF	Citations
109	Functional Lecithin:Cholesterol Acyltransferase Deficiency and High Density Lipoprotein Deficiency in Transgenic Mice Overexpressing Human Apolipoprotein A-II. Journal of Biological Chemistry, 1996, 271, 6720-6728.	1.6	68